A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

Study Summary

APT-008 is an open-label, Phase I/Ib, dose escalation and expansion cohort study to evaluate the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and preliminary efficacy of EOS301984 as monotherapy and in combination with other anticancer therapies in participants with advanced solid tumors.

Conditions

Advanced Solid Tumors

Interventions / Drugs

EOS301984 Anti-PD-1 monoclonal antibody

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment55 participants

Primary Completion—

Lead SponsoriTeos Therapeutics

Data Retrieved2026-04-11 04:18:14.528925+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.